XML 54 R40.htm IDEA: XBRL DOCUMENT v3.6.0.2

LICENSE AGREEMENTS (Details)			3 Months Ended		12 Months Ended
	Sep. 15, 2016 USD ($) item	Dec. 15, 2014 USD ($) item	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
LICENSE AGREEMENTS
License fee revenue					$ 6,162,000	$ 1,371,000	$ 1,153,000
Collaboration revenue						35,000,000
Accrued collaboration charges					3,367,000	$ 2,328,000
Janssen Biotech | License agreements
LICENSE AGREEMENTS
Collaboration revenue				$ 35,000,000
Accrued collaboration charges					$ 3,367,000
Janssen Pharmaceuticals | License agreements
LICENSE AGREEMENTS
Upfront payment received under license agreement	$ 5,000,000
License fee revenue			$ 5,000,000
Least number of products under License Agreement | item	1
Aggregate maximum total payments for development and regulatory milestones under license agreement	$ 75,000,000
Tiered royalties percentage range	low single digit
Initial Period | Janssen Biotech | License agreements
LICENSE AGREEMENTS
Upfront payment received		$ 35,000,000
Number of agreed upon studies | item		2
Percentage of costs to be paid by Geron		50.00%
Percentage of costs to be paid by Janssen		50.00%
Notification period		24 months
Maximum period Geron is obligated to procure supply for manufacturing imetelstat under collaboration agreement		9 months
U.S. Opt-In Rights exercised | Janssen Biotech | License agreements
LICENSE AGREEMENTS
Percentage of costs to be paid by Geron		20.00%
Percentage of costs to be paid by Janssen		80.00%
Continuation Election milestone payment		$ 65,000,000
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement		470,000,000
Aggregate maximum total of payments for sales milestones under collaboration agreement		$ 350,000,000
Tiered royalties percentage, low end of the range		mid-teens
Tiered royalties percentage, high end of the range		low twenties
U.S. selling effort percentage		20.00%
U.S. Opt-In Rights not exercised | Janssen Biotech | License agreements
LICENSE AGREEMENTS
Continuation Election milestone payment		$ 65,000,000
Full U.S. Rights fee		70,000,000
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement		415,000,000
Aggregate maximum total of payments for sales milestones under collaboration agreement		$ 350,000,000
Tiered royalties percentage, low end of the range		double-digit
Tiered royalties percentage, high end of the range		mid-teens
Collaborative Arrangement IP Exclusively Licensed | Janssen Biotech | License agreements
LICENSE AGREEMENTS
Percentage of costs to be paid by Geron		50.00%
Percentage of costs to be paid by Janssen		50.00%
License Arrangement IP Exclusively Licensed | Janssen Pharmaceuticals | License agreements
LICENSE AGREEMENTS
Percentage of license agreement costs to be paid by Geron	50.00%
Percentage of license agreement costs to be paid by Jassen Pharmaceuticals	50.00%

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable to collaboration partner for which invoices have not yet been received under the respective collaboration agreement (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementAccruedCollaborationChargesCurrent
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of consideration that Geron will receive upon Janssen providing a positive Continuation Election notice.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementContinuationElectionMilestonePayment
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the aggregate maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the maximum period that Geron is obligated to Janssen to procure supply for manufacturing imetelstat under the collaboration agreement

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementDrugSupplyProcurementPeriodMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the consideration that Geron will receive from Janssen upon Geron's decision to opt-out of further development cost sharing after Janssen's positive Continuation Election notice.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementFullUSRightsFee
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the percentage of costs that Geron must pay during certain phases of the agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementGeronCostSharingPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of costs that Janssen must pay during certain phases of the agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementJanssenCostSharingPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the latest notification period from Janssen to Geron in the event of early termination or suspension of the Initial Phase 2 MF Study.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementNotificationPeriod
Namespace Prefix:	gern_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of agreed upon studies.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementNumberOfStudies
Namespace Prefix:	gern_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the aggregate maximum consideration that Geron could receive from attaining certain sales milestone events under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementSalesMilestonesAggregateMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the percentage of sales effort that Geron can provide in lieu of funding the same percentage of promotion costs upon regulatory approval and commercial launch of imetelstat in the U.S.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementSellingEffortPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the high end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementTieredRoyaltiesPercentageHighEndOfRange
Namespace Prefix:	gern_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the low end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat.

+ References

No definition available.

+ Details

Name:	gern_CollaborativeArrangementTieredRoyaltiesPercentageLowEndOfRange
Namespace Prefix:	gern_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the least number of products required to be developed under the License Agreement.

+ References

No definition available.

+ Details

Name:	gern_LeastNumberOfProductsUnderLicenseAgreement
Namespace Prefix:	gern_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the license agreement.

+ References

No definition available.

+ Details

Name:	gern_LicenseAgreementDevelopmentAndRegulatoryMilestoneAggregateMaximum
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the percentage of costs Geron must pay during certain phases of the license agreement.

+ References

No definition available.

+ Details

Name:	gern_LicenseAgreementGeronCostSharingPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of costs that Janssen Pharma must pay during certain phases of the license agreement.

+ References

No definition available.

+ Details

Name:	gern_LicenseAgreementJanssenPharmaCostSharingPercentage
Namespace Prefix:	gern_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the range of tiered royalty percentages to be applied to worldwide net sales of licensed products under the License Agreement.

+ References

No definition available.

+ Details

Name:	gern_LicenseAgreementTieredRoyaltiesPercentageRange
Namespace Prefix:	gern_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

No definition available.

+ Details

Name:	gern_LicensesAndRoyaltyRevenue
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront payment received from Janssen upon effectiveness of Collaboration Agreement.

+ References

No definition available.

+ Details

Name:	gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront payment under License Agreement.

+ References

No definition available.

+ Details

Name:	gern_UpfrontPaymentUnderLicenseAgreement
Namespace Prefix:	gern_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=gern_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=gern_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=gern_InitialPeriodMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=gern_RightsExercisedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=gern_RightsNotExercisedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=gern_CollaborativeArrangementIPExclusivelyLicensedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=gern_LicenseArrangementIPExclusivelyLicensedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: